Agilent

Agilent Technologies Fiscal Q2 Revenues Rise 5 Percent

In Brief This Week: BioMérieux, LumiraDx, Chembio Diagnostics, Quanterix, Quest Diagnostics, More

Agilent Obtains CE-IVD Mark for CDx to ID Cervical Cancer Patients Suitable for Keytruda

Agilent Expands CE-IVD Mark for Companion Dx Tests Alongside BMS European Opdivo Approvals

Agilent Fiscal Q1 Revenues Rise 8 Percent; Firm Increases FY22 Guidance

In Brief This Week: Roche, Seegene, SQI Diagnostics, Agilent Technologies, and More

JP Morgan Healthcare Conference Day 2: Labcorp, Thermo Fisher Scientific, Abbott, Danaher, More

Agilent Q4 Revenues Rise 12 Percent

In Brief This Week: PerkinElmer, Labcorp, Illumina, Thermo Fisher Scientific, and More

Agilent Gets CE Mark for Expanded Use of PD-L1 CDx in Triple-Negative Breast Cancer

Agilent Obtains CE Mark for CDx to Guide Treatment With Immunotherapeutic Agent Opdivo

FDA Approves Agilent Technologies CDx for Breast Cancer Drug Verzenio

In Brief This Week: PerkinElmer, Chembio, Becton Dickinson, Fulgent Genetics, and More

Agilent, Visiopharm Ink Distribution Agreement for AI-Based Digital Pathology Software

Agilent Technologies Gets CE-IVD Mark for Expanded Use of PD-L1 CDx in Esophageal Cancer

Agilent Technologies, Partek Partner on End-to-End Bioinformatics Workflow

Agilent Technologies Q3 Revenues Rise 26 Percent

Agilent Technologies Obtains CE Mark for Expanded Use of PD-L1 CDx in NSCLC

Agilent Technologies, Thomas Scientific Ink Distribution Agreement for Genomics Products

Agilent Q2 Revenues Rise 23 Percent